文献速递糖尿病

每周一次胰高血糖素样肽1受体激动剂阿必鲁肽对多种胰岛素治疗控制不佳的2型糖尿病患者血糖控制及减少餐时胰岛素用量的影响:一项随机试验

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
PubMed 文献 · Diabetes Care · 2020-07-21

该研究在多种每日胰岛素注射方案控制不佳的2型糖尿病患者中,测试用每周一次GLP-1受体激动剂阿必鲁肽替代餐时胰岛素赖脯胰岛素的原则。经4周基础+餐时胰岛素优化后随机1:1分为阿必鲁肽+优化基础甘精胰岛素+赖脯胰岛素(随机时减量50%,4周后完全停用赖脯胰岛素)(n=402)或继续优化赖脯+甘精胰岛素(n=412)。第26周HbA1c降幅阿必鲁肽+甘精组非劣效于赖脯+甘精组,54%参与者完全替代餐时胰岛素,体重降低且严重/记录的症状性低血糖更少。

要点

  • 阿必鲁肽+甘精胰岛素组第26周HbA1c降幅非劣效于赖脯+甘精胰岛素组(LS差异0.06%,95%CI -0.05至0.17;非劣效性P<0.0001)。
  • 阿必鲁肽+甘精胰岛素组54%(218例)参与者完全替代餐时胰岛素且至第26周未重新使用赖脯胰岛素。
  • 阿必鲁肽+甘精胰岛素组第26周每日餐时胰岛素总量较基线降低62单位/天(95%CI -65.9至-57.8;P<0.0001),每周注射总次数从29次降至13次。

核心结论

  • 每周一次GLP-1受体激动剂能在54%的2型糖尿病患者中替代餐时胰岛素,大幅减少餐时胰岛素注射次数;血糖控制改善,并伴有体重降低和低血糖更少的额外获益。
  • 用每周一次GLP-1受体激动剂替代餐时胰岛素可简化基础+餐时胰岛素治疗方案,并在2型糖尿病中取得更好的结局。

研究设计与样本

  • 这是一项达标治疗(treat-to-target)研究,在4周基础+餐时胰岛素优化后,将参与者按1:1随机分配至阿必鲁肽+优化基础甘精胰岛素+赖脯胰岛素(随机时赖脯胰岛素减量50%,4周后完全停用)(n=402)或继续优化赖脯胰岛素+优化甘精胰岛素(n=412)。

主要发现

  • 基线HbA1c均值±SD在阿必鲁肽+甘精胰岛素组为7.8±0.6%(61±7 mmol/mol),在赖脯+甘精胰岛素组为7.7±0.6%(60±7 mmol/mol);第26周分别降至6.7±0.8%(49±8 mmol/mol)和6.6±0.8%(48±8 mmol/mol),最小二乘(LS)差异0.06%(95%CI -0.05至0.17),非劣效性P<0.0001。
  • 阿必鲁肽+甘精胰岛素组中218例参与者(54%)完全替代了所有餐时胰岛素,且至第26周未重新使用赖脯胰岛素。
  • 每日餐时胰岛素总量在基线时两组相似,但第26周阿必鲁肽+甘精胰岛素组降低62单位/天(95%CI -65.9至-57.8;P<0.0001),且每周注射总次数从29次降至13次。
  • 严重/记录的症状性低血糖发生率阿必鲁肽+甘精胰岛素组为57.2%,赖脯+甘精胰岛素组为75.0%;体重变化LS均值±SE在阿必鲁肽+甘精胰岛素组为-2.0±0.2 kg,在赖脯+甘精胰岛素组为+2.4±0.2 kg(P<0.0001)。
  • 胃肠道不良事件发生率阿必鲁肽+甘精胰岛素组为26%,赖脯+甘精胰岛素组为13%。

关键数值与推荐

  • 非劣效性界值原文未报告。
  • 阿必鲁肽+甘精胰岛素组第26周HbA1c为6.7±0.8%(49±8 mmol/mol),赖脯+甘精胰岛素组为6.6±0.8%(48±8 mmol/mol),LS差异0.06%(95%CI -0.05至0.17)。
  • 阿必鲁肽+甘精胰岛素组每日餐时胰岛素总量较基线降低62单位/天(95%CI -65.9至-57.8;P<0.0001)。
  • 严重/记录的症状性低血糖发生率阿必鲁肽+甘精胰岛素组57.2% vs 赖脯+甘精胰岛素组75.0%。
  • 体重变化LS均值±SE阿必鲁肽+甘精胰岛素组-2.0±0.2 kg vs 赖脯+甘精胰岛素组+2.4±0.2 kg(P<0.0001)。

临床怎么用

  • 作者认为,用每周一次GLP-1受体激动剂替代餐时胰岛素可简化基础+餐时胰岛素治疗方案,并在2型糖尿病中取得更好的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The principle of replacing prandial insulin lispro with a once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) for type 2 diabetes inadequately controlled on a multiple daily insulin injections regimen was tested with albiglutide. RESEARCH DESIGN AND METHODS: In this treat-to-target study, basal plus prandial insulin was optimized over 4 weeks before participants were randomized (1:1) to albiglutide plus optimized basal insulin glargine and lispro (dose reduced by 50% at randomization; subsequently, lispro injections were fully discontinued 4 weeks later) (n = 402) or to continued optimized lispro plus optimized glargine (n = 412). RESULTS: Mean ± SD HbA1c at baseline, 7.8 ± 0.6% (61 ± 7 mmol/mol) in the albiglutide + glargine group and 7.7 ± 0.6% (60 ± 7 mmol/mol) in the lispro + glargine group, was reduced at week 26 to 6.7 ± 0.8% (49 ± 8 mmol/mol) and 6.6 ± 0.8% (48 ± 8 mmol/mol), respectively (least squares [LS] difference 0.06% [95% CI -0.05 to 0.17]; noninferiority P < 0.0001). In the albiglutide + glargine group, 218 participants (54%) replaced all prandial insulin without reintroducing lispro up to week 26. Total daily prandial insulin dose was similar at baseline but was lower by 62 units/day (95% CI -65.9 to -57.8; P < 0.0001) at week 26 in the albiglutide + glargine group, and the total number of weekly injections was also reduced from 29 to 13 per week. Less severe/documented symptomatic hypoglycemia (57.2% vs. 75.0%) occurred in the albiglutide + glargine group with meaningful weight differences (LS mean ± SE -2.0 ± 0.2 vs. +2.4 ± 0.2 kg; P < 0.0001) vs. lispro + glargine. Gastrointestinal adverse events were higher with albiglutide + glargine (26% vs. 13%). CONCLUSIONS: A once-weekly GLP-1RA was able to substitute for prandial insulin in 54% of people, substantially reducing the number of prandial insulin injections; glycemic control improved, with the added benefits of weight loss and less hypoglycemia in the GLP-1RA arm. Replacing prandial insulin with a weekly GLP-1RA can simplify basal plus prandial insulin treatments and achieve better outcomes in type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rosenstock J, Nino A, Soffer J, et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care. 2020. PMID: 32694215. doi:10.2337/dc19-2316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。